Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00754325 · ClinicalTrials.gov registry record · Phase 2

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

A Phase 2 study of Advanced Breast Cancer, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 2
Development phase
100
Enrollment target
20
Study locations

NCT00754325 is a Phase 2 study of Advanced Breast Cancer that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 100 participants, below the 461-participant average among 28 other Advanced Breast Cancer trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00754325, a Phase 2 study of Advanced Breast Cancer, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 2
Development phase
100 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to find out what effect the combination of fulvestrant (Faslodex) and dasatinib (Sprycel) has on advanced breast cancer compared to fulvestrant alone.

Conditions Studied

Advanced Breast Cancer

Interventions

  • DRUG Fulvestrant
  • DRUG Dasatinib

Study Locations (20)

Texas

  • Texas Oncology-Central Austin Cancer Center - Austin
  • Texas Oncology, P.A. - Bedford
  • Texas Oncology, P.A. - Dallas
  • Texas Oncology - Dallas
  • Texas Oncology Sammons Cancer Center - Dallas
  • Texas Cancer Center - Denton
  • El Paso Cancer Treatment Ctr - West - El Paso
  • Us Oncology Research, Inc. - Houston

Arizona

  • Northern Arizona Hematology & Oncology Associates - Sedona
  • Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope - Tucson

Florida

  • Florida Cancer Institute - New Hope - Hudson
  • Cancer Centers Of Florida, P.A - Ocoee

Oregon

  • Willamette Valley Cancer Center - Eugene
  • Northwest Cancer Specialists, P.C. - Portland

Indiana

  • Central Indiana Cancer Centers - Carmel

Kansas

  • Kansas City Cancer Center, Llc. - Overland Park

Minnesota

  • Minnesota Oncology Hematology, P.A. - Minneapolis

Missouri

  • Missouri Cancer Associates - Columbia

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2008-09
Est. Completion 2014-01
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00754325

The ClinicalTrials.gov registry entry for NCT00754325 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 461-participant average among 28 other Advanced Breast Cancer trials with a reported enrollment target (78% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Fulvestrant is the first listed.

NCT00754325 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Texas, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT00754325 about?

NCT00754325 is a clinical study titled "Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor". The purpose of this study is to find out what effect the combination of fulvestrant (Faslodex) and dasatinib (Sprycel) has on advanced breast cancer compared to fulvestrant alone.

What is the current status of trial NCT00754325?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2008-09. Estimated completion is 2014-01.

What conditions does trial NCT00754325 study?

This clinical trial studies the following conditions: Advanced Breast Cancer.

What interventions are being tested in trial NCT00754325?

The interventions under investigation include: Fulvestrant (DRUG), Dasatinib (DRUG).

Who is sponsoring clinical trial NCT00754325?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00754325 being conducted?

This trial has 20 study locations across Arizona, Florida, Indiana, Kansas, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Breast Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.